Mstone Portfolio Company, Epygenix Therapeutics, Announces Agreement to be Acquired For Total Deal Value of $680M
HONG KONG SAR, May 2, 2024 /EINPresswire.com/ -- Mstone Partners (“Mstone”), an entrepreneurial biotech incubator in the form of a holding company, today announces that Epygenix Therapeutics, Inc. (“Epygenix”), an Mstone portfolio company, …